New approach developed by Dr. Rakesh Jain and his research team identifies biomarkers that may indicate which patients will best respond to immune checkpoint blockade therapies. A research team led by NFCR-supported scientist Rakesh K. Jain, PhD, the Andrew Werk Cook Professor of Tumor Biology at Harvard Medical School and…...